Senni M, et al. - This post hoc analysis of the TITRATION trial was performed to assess the link between baseline systolic blood pressure (SBP) at screening and achievement of the target dose of sacubitril/valsartan of 97 mg/103 mg (also termed ‘LCZ696 200 mg’) twice per day during the study. Findings demonstrated that if the treatment was titrated gradually, the majority of patients (>80%) with SBP of ≥100 mmHg achieved and maintained the target dose of sacubitril/valsartan. Based on the findings, it was recommended that low SBP should not prevent clinicians from considering the initiation of sacubitril/valsartan.